List of Therapeutic Companies in India - 63

Advancells offers stem cells for various chronic conditions and lifestyle disorders.

Ahammune Biosciences Pvt. Ltd. is a startup company based in Pune. Ahammune Biosciences is an innovation-led drug discovery company started in 2016 which focuses on developing new treatment options for immune mediated diseases of the skin. Our current program is on the depigmenting disorder, Vitiligo. The current treatments for Vitiligo provide only temporary and symptomatic relief. Thus, there is an enormous unmet global need in treating patients with Vitiligo. The mission of Ahammune Biosciences is to arrest the progress of Vitiligo and to induce re-pigmentation of depigmented patches. We are committed to take our innovation-driven drug discovery platform to the next level to demonstrate to the world that we as a nation can foster new molecules for complex diseases.

APAC BIOTECH strives to find roots of cancer - the world's alarming disease, by transforming the promise of technology and knowledge of oncology into therapies that have the power to restore health and even save lives of cancer patients. A Biotechnology Company focused on Research and Manufacturing Of Cell Based Immunotherapy treatment for Cancer

Since 1978, Appasamy Associates and Group of companies have been leading manufacturers and distributors of Ophthalmic Diagnostic & Surgical Equipments, Intraocular Lenses (IOLs), Microsurgical Instruments and Ophthalmic Pharmaceuticals. Our four decades of work have been widely appreciated throughout the world. Our dedication to support our products had become a bench mark among the community. We have dedicated R & D team to fulfil state of the art requirements of the ophthalmic community. We strive hard to make each and every modern technology and equipment within the easy reach of ophthalmic surgeons and visions care professionals in India. Our various manufacturing facilities at Chennai, Pondicherry and Baddi have got quality systems certifications audited by TUV, DNV and ITC for ISO 9000 and ISO 13485 requirements. The certifications bodies also provided CE marking for various products.

Aurigene Pharmaceutical Services is leading contract research, development, and manufacturing organization (CDMO). Built on the legacy of accelerating innovation and backed by a vast experience in drug discovery and development our mission is to relentlessly work for the success of our clients and to build long term relationships through a holistic approach to accelerate the journey of a molecule from laboratory to market. By providing access to our resources, knowledge and experience, we create success for our clients and ultimately patients. We offer integrated and standalone services for medicinal chemistry, biology, preclinical services, DMPK studies, development and manufacturing for clinical phase I-III programs, regulatory submission batches and commercial manufacturing. A differentiating factor is the integrated API and formulations service that spans from key starting material, advanced intermediates, APIs to finished products such as oral solids, sterile products, nasal solutions etc. Our development services in India are complemented by cGMP commercial manufacturing facilities in the UK, Mexico, USA and India.

Beta Drugs Ltd. is a dedicated world leader in oncology. BDL is a Global leader in the development of enabling products, scientific knowledge, and technical expertise within a wide range of applications. At Beta DrugsLtd. (BDL.) we are improving both the speed to market of our products and the value of our product introductions to customers. Inspired by a newly-formed breakthrough innovation group, Beta Drugs Ltd. (BDL.) is actively exploring opportunities that stretch business and technology boundaries.

Established in 2002 into API manufacturing, we have a consolidated position in the domestic and global market for the API Business. In today's dynamic global pharmaceutical market, we at BDR Pharmaceuticals have carved a niche for ourselves, with our formulations portfolio for specialty medication. Our unique strategy of multi-branding ensures that critical and lifesaving medicines are available at affordable prices with two API and formulation facilities at Gujarat, Uttarakhand and a pellet facility at Hyderabad.

Bharat Biotech International Limited is a multidimensional biotechnology company specializing in product-oriented research and development leading to the manufacture of vaccines and bio-therapeutics in Hyderabad, India. Bharat Biotech was established in the year 1996 by Dr. Krishna M. Ella and Mrs. Suchitra K. Ella. Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities. Our mission is to deliver affordable, safe and high-quality vaccines and bio-therapeutics that help people prevail over diseases. We seek to lead innovation in biotechnology in order to lead the fight against disease with a focus on emerging markets. Our significant R&D investments have yielded several breakthroughs including the world’s 1st Eco-friendly recombinant Hepatitis-B vaccine (free of cesium chloride and Thiomersal).Rotavirus vaccine from a naturally attenuated strain,Typhoid Conjugate vaccine. Transparency and openness are central to our DNA. An uncompromising commitment to integrity differentiates us. Our clinical trials are known for their rigor and breadth. We also adopt the most comprehensive data integrity procedures to ensure that we capture, store and report data accurately. We are committed to provide affordable and innovative vaccines for healthier lives. Bharat Biotech launched India’s first recombinant Epidermal Growth Factor (REGEN-D®) to combat diabetic foot ulcers, burns. Typbar TCV® is the world’s first clinically proven conjugate Typhoid vaccine and received WHO-Prequalification in January 2018. ROTAVAC® was India’s first and largest efficacy clinical trial on vaccines and Rotavac® received WHO-Prequalification in January 2018. Bharat Biotech Launches ROTAVAC 5D®- Lowest dose volume Rotavirus vaccine - ROTAVAC in the world launched in December 2019. COVAXIN, India's indigenous COVID-19 vaccine by Bharat Biotech.

Bharat Serums And Vaccines Limited (BSV) is one of the fastest growing biopharmaceutical companies in India. For 50 years now, BSV has used its scientific resources to develop a range of biological, biotech and pharmaceutical products. Today, as we influence patient outcomes in the therapeutic areas of Women’s health and Critical Care and IUI-IVF, we have the privilege of being a partner of choice. BSV's product portfolio includes plasma derivatives, monoclonals, fertility hormones, antifungals, anaesthetics, cardiovascular drugs, and equine immunoglobulin /antitoxins. In addition, BSV offers products in the areas of gynaecology, assisted reproductive technology, critical care, emergency medicine, neurology, nephrology, haematology, and urology. The company provides its products to retail outlets and hospitals through distributors primarily in India, as well as in the Asia Pacific, the Russian Federation, CIS countries, Latin America, Africa. BSV is amongst the top 10 Biotech companies in India. The Company has in its portfolio over 145 brands. The company has over 1000 employees selling its products across the country. Our brands are marketed all over India and exported to over 70 countries across the world We have an open and entrepreneurial culture, with each of our employees taking on significant responsibility in each activity of our value chain, be it in terms of research & development, manufacturing, quality, sales & marketing, distribution, business development or organisation building. Advent International, a global private equity firm has endorsed its faith in our commitment towards bringing life to life

Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high. The early anticipation of the increasing dominance of biologics in global development pipelines helped us to be ahead of the curve in crafting a differentiated product portfolio based on fermentation and recombinant technologies, which straddles fermentation-derived small molecules and biologics, both novel as well as biosimilars. The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppresants and other specialty products has made us a leading global supplier of these products. We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders. Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Our insulin products have made a difference to the lives of millions of people with diabetes across the globe. We now aim to provide our insulin products to ‘one in five’ people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years. We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the USFDA; Ogivri™, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the US. In addition to Trastuzumab, several of our biosimilar assets are on track for anticipated regulatory approvals in developed markets. We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin. Through our subsidiary, Syngene, we offer a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) to the global life sciences sector. Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through ‘blockbuster’ drugs with the potential to benefit a billion patients.

Biodeal Pharma is a WHO-GMP Certified and PIC/S approved pharmaceutical manufacturing Company and is a highly respected name as a fully integrated Indian Manufacturing Company located amidst the green fields of Himachal Pradesh and are leading global providers in Pharmaceuticals, Cosmetics and Nutraceuticals. Owing to persistent values of customer satisfaction, unsurpassed quality standards, human safety, innovation and serves a clientele of more than 30 reputed companies like TORRENT, DRL, SUN PHARMA, DR. MOREPEN, CADILA, ZYDUS, ALEMBIC, ALKEM, WOCKHARDT, INTAS, ZUVENTUS, IPCA, INDOCO, MACLEODS , KOYE PHARMA, ERIS LIFESCIENCES , AJANTA PHARMA, etc. BIODEAL offers Products on Third Party Basis for Export as well as Domestic business on contract manufacturing basis. Our Sections:- • Tablets (Drugs & Nutraceuticals) • Capsules (Drugs & Nutraceuticals) • Dry Powder Inhaler Capsules • Oral Spray (Food) • Dry Sachet • Dusting Powder • Nasal Sprays • Lotion • Ointment • Cosmetics Biodeal has a strong presence in NUTRACEUTICALS with VITAGEN, offering Vitamins, Multi complex, Antioxidants, Amino acids, Omegas, Herbals and varied categories to meet specific needs. Besides most common tablet or capsule formats, VITAGEN offers the biggest range of innovative delivery forms which are easy to consume and have a great taste, e.g., Spray, Chewable, Sachets. The large number of bioavailable and well absorbed products provides the opportunity for everyone to be able to get a Nutrition therapy according to individual needs. Also introducing all new range of VITAGEN Sunscreens, specifically developed formulations for sun protection and skin care. Vegetarian prebiotic capsule is used in all the products, which are generally better consumed by digestive system, and ideal for those who do not want to take animal gelatin for moral, diet or religious reason, as well as opting for a healthier alternative.

Later part of the bygone twentieth century has witnessed a major revolution in the field of life-sciences. Researches carried out during this period, particularly in the area of molecular biology and recombinant technology, have led to emergence of 'Biotechnology'​ with a new face. Plants, animals and microorganisms being a key component of our ecosystem have always remained at centre-stage of research for different purposes as they affect the human life. Development of culture methods, better understanding about molecular biology, discovery of restriction endonucleases and their use in mapping of DNA laid the foundation stone for modern day biotechnology. Isolation of thermostable DNA polymerase along with the development of PCR technique made cloning simplified and providing way for rec-DNA technology. Further developments were generation of bar-code like DNA fragment patterns of genomic DNA. These patterns appeared useful in distinguishing individuals based on DNA sequence variations among them. Such variations of DNA among organisms were termed as fingerprints or profiles which provide a versatile tool to characterize genetic variability, genome evolution, population genetics, taxonomy, breeding and diagnostics even today! The technology to read the DNA base-by-base made it possible to identify useful genes. This information which could be cloned in suitable vectors and introduced in appropriate hosts through a variety of gene transfer methods gave an impetus to genetic improvement programmes and production of Genetically modified organisms. Today the genomic sequencing is contributing to identify the basis of pathology, providing tailored therapies. We are quickly advancing towards the in situ engineering of the genomic information to achieve designer humanity. Bioheaven ventures into this space "Turning Human Needs into Careful Solutions"​..........

Biophore is a research driven global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) having its operations based in Hyderabad, India and also has a registered office in New Jersey, USA. Biophore has two dedicated R&D facilities in Hyderabad and Vishakapatnam. The research facilities are fully equipped with wide range of R&D and process equipment from USA with reaction capabilities from milligram to kilogram. Ever since its establishment in 2007, Biophore recognized that there were two ways of growing the API business: manufacture a large API product basket, or pick a handful of promising APIs in select therapeutic categories and grow them over the long-term. Biophore consciously chose the latter option and focused on not only building competencies and adding scale in those segments but more importantly, building efficiencies that would make it an undisputed leader in these products of choice. The product range is constantly expanded through its own R&D, process development, technology transfers, joint ventures and collaborations. Biophore's core strength lies in development of non – infringing routes for comprehensive range of bulk actives and intermediates, development of niche APIs, oncology APIs, APIs for MRI contrast agents and APIs for NCE - 1 filing. Biophore has made strategic investments in two manufacturing facilities. Sionc pharmaceuticals & Azico – Biophore, Both located at Vishakapatnam. Among them Sionc, a multi-purpose plant has passed FDA inspection in 2013 & 2016 with no observations on the Form 483. This is the reason to be proud and confirmation of the highest quality standards of Biophore. Our other facility Azico – Biophore is also a n FDA approved facility that strictly complies with cGMP procedures and maintains well documented SOPs, with a modern quality control laboratory thereby ensuring the production of highest quality APIs.

Path breaking solutions to large unmet needs in Antimicrobial resistance (AMR) and immuno-oncology. Making highly differentiated assets, affordable and accessible to all of humanity.

Founded by Shri I.A. Modi, Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last seven decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over hundred other countries around the world. Focused strongly on Innovation and Research, the company is present in more than forty-five therapeutic areas spread across twelve specialities, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. At Cadila Pharmaceuticals, Research and Development is at the core of all its initiatives, be it Biotechnology, APIs, Formulations, Plant Tissue Culture or Phytochemistry. More than 300 scientists in its various Research and Development setups reinforce the competitiveness of research in the therapeutic areas which have high unmet medical needs. Cadila Pharmaceuticals Excellence in manufacturing facilities is central to Cadila Pharmaceuticals. The company’s formulations manufacturing plant at Dholka near Ahmedabad, Gujarat is spread over hundred acres of land. This state-of-the- art facility is not only impressive in size, but is also USFDA approved. The second formulations manufacturing facility is located at Samba in Jammu and Kashmir. The facility meets most of the stringent quality standards across the globe to produce tablets, capsules, soft and hard gelatin capsules, liquids and orals. Two Active Pharmaceutical Ingredient (API) manufacturing units at Ankleshwar, Gujarat manufacture a wide range of APIs and intermediates including many USFDA-certified products. The company has strong foothold in the African continent through its formulation manufacturing facility at Addis Ababa in Ethiopia. For more information visit: https://www.cadilapharma.com/

Calyx Chemicals & Pharmaceuticals Ltd. is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates, based in India. With over 40 years of experience, the company operates a US FDA-inspected facility in Tarapur, Maharashtra. It specializes in APIs for anti-TB and anti-malarial therapeutic areas and offers custom synthesis of pharmaceutical intermediates. Calyx provides integrated services through its Contract Research and Manufacturing Services (CRAMS), which encompass API development and contract manufacturing. The company has a strong regulatory compliance record, having successfully passed audits from USFDA, EDQM, and WHO. It serves a global customer base, focusing on regulated markets such as the US and Europe.

CELLIX BIO - Founded in 2014, we are the leading drug discovery and development company. We generate our own drug design data before combining the critical power of AI with the creativity of involving proprietary platform technology, Synergix AI, and the expertise of our world-class scientists. This allows us to shorten the pre-clinical drug discovery stage and, in turn, substantially accelerate the delivery of new treatments to patients worldwide. By reducing the number of compounds analysed, we aim to vividly reduce the time and cost of discovering and developing new medicines. Cellix Bio balances Synergix AI plus human creativity in drug discovery.

Century Pharmaceuticals Ltd is a privately held Pharmaceutical Company based out Vadodara, India. For more than 30 years, we have emerged as a respectable name in the industry. Our services include manufacturing APIs, facilities for contract manufacturing, Biotechnology research, API research, stability studies, and more.

"We are a company based in India, responsibly offering pharmaceutical products across the globe!" We are a public listed company. We are associated with many companies worldwide. We export from India various API & intermediates, pharmaceutical products, critical care injections, plasma, blood, biological products across the globe. We import vaccines in India from the top most manufacturers of the world. We have our own marketing team in India. Our team promotes our brand pharmaceutical formulations, especially injectables We have an excellent sourcing & qualified supply & regulatory team.

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

CLONZ  is a biopharmaceutical firm promoted by a group of young and passionate Biotechnologists, focused on the development, manufacturing and commercialization of Human Therapeutic  biosimilar Monoclonal Antibodies (MAbs).   Clonz got incorporated in 2009  and started its operations in September 2010 at Genome Valley, Hyderabad, India With experienced team coming from recognized leaders in recombinant biosimilar manufacturing, Clonz is committed to delivering quality biologics to make treatment and care affordable to the world population in many disease indications, with special emphasis on Oncology. DSIR (Govt.of India) Recognised R&D unit with fully integrated Mammalian platform to Develop Biosimilar MAbs

Concept Medical Inc. is a Research-oriented organization. It is into the development of a novel drug-eluting balloon catheter (DEB) using the latest Nano Technology. Aim of CMI is to develop innovative and revolutionary medical devices for the treatment of Cardiovascular Diseases. Concept Medical Inc. was incorporated on June 2008 in Cleveland OH. Later on, the company moved to San Jose, California. Currently, the company has a Business Development office with its Main Research Unit located at Surat, India. Concept Medical Inc. has set up a full-fledged research center which is involved in the development of Nanocarrier based drug delivery technology. Its team of Scientists and Engineers hold International Patents on research. Concept Medical Research Pvt. Ltd. has featured on Indian Government's list of top ten companies in the Pharmaceutical sector for its research in Medical Device technology. Our core development areas and offerings include drug delivery technologies comprising of various types of coatings, nanoparticles, and nanocarrier delivery systems, and coatings that have pro healing properties, and biocompatibility capabilities. Our strategy is to build on our strong technical leadership in the field of Nano carrier-based drug delivery and products, visioning to strengthen our position as an innovative and resourceful product development partner to the Medical Device industry.

CrisprBits was started by entrepreneurs and scientists with extensive industry and academic experience, including in the biological sciences. We have prior experience in developing diagnostic solutions, precision medicine and clinical-research solutions that are used by pharmaceutical and biotechnology companies in India and around the world. We are motivated by three guiding principles: using deep science to deliver high quality products; adhering to the highest ethical standards, including in the choice of products we offer; and developing an organization that draws exceptional individuals with diverse backgrounds and affinities. We have offices in Delhi and Bengaluru. Our lab is located in C-CAMP, a premier incubator for biotechnology innovation in Bengaluru.

Curadev - We are a small molecule drug discovery biotech with an exciting portfolio of research programs that have yielded patent protected drug candidates. Founded in 2010, Curadev has created a premier translational research organization known for prescient target selection and high quality, data-driven program execution. Our programs seek to ameliorate disease by translating cutting edge discoveries into new medicines. We have swiftly established our credentials by successfully creating and out-licensing our small molecule patents in immune-oncology.

East Ocyon Bio Private Limited: Advancing Cell and Gene Therapy East Ocean Bio Private Limited is a leading cell and gene therapy company headquartered in India. We are committed to advancing the development and delivery of cell and gene therapies to patients around the world. Our team of experienced scientists and clinicians is dedicated to developing innovative cell and gene therapies that can address unmet medical needs. We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of cancer. Our proprietary technology is designed to harness the power of these important pathogen-fighting immune cells and is uniquely capable of enhancing their ability to search and destroy tumor cells.

Epygen Biotech private limited is a Biotechnology organization promoted by the founders of Epygen Labs, bringing along decades of precious experience in Biotech research and successful business. With offices, labs and manufacturing facilities in Dubai, India and USA, Epygen Biotech exhibits unique capabilities in the Biotechnology field, where it has developed a strong pipeline of therapeutic proteins for Cardiovascular, Oncology and Immune disorders. With focus on Biosimilars and Novel Biologic Entities, Epygen utilizes its skills in molecular biology, fermentation and protein engineering to produce Biologics in an affordable way, meeting global regulatory standards.

ExoCan Healthcare Ltd is a clinical stage company developing exosome based liquid biopsy tests. We are one of the first few exosome companies globally and India's first exosome company established in 2015. ExoCan developed a patented exosome workflow which is world's fastest, and most efficient. We are committed to bring change in cancer precision medicine with our ever growing portfolio of exosome technologies.

EXSURE is an R & D-based startup and we are developing the next generation of exosome-based cancer therapeutics. We are developing a unique exosome-based chemotherapeutic drug-delivery platform that will facilitate precise and guided delivery of anti-cancer drugs (existing on the market) into tumor cells and relapse-causing cells (cancer stem cells) without abruptly harming the healthy cells. Our platform will reduce chemotoxicity and chances of cancer relapse in cancer patients. Currently, we are working with a breast cancer model. We have validated the efficiency and efficacy of our platform in vitro (in different breast cancer cell lines and derived cancer stem cells) and ex-vivo (primary cells & stem cells derived from chemo-naive clinical samples of breast tumor biopsies). We are yet to validate our platform in vivo (SCID mice). We have filed the patent for the formulation we are using to develop these bioengineered drug-loaded targeted exosomes and the methodology behind it (Final patent to be filed this month). We are providing outsourcing services including any type of cell-culture-based assays, exosome-based experimentations, and cancer stem cell-based assays.

Fibroheal Woundcare Pvt Ltd is a startup approved under Startup India and Startup Karnataka and winner of National Technology Award under startup category & working on leveraging biomaterial property of silk to innovate and develop various biomedical application of silk proteins to address different healthcare needs. we are supported by by DBT, Government of India, Center for cellular and molecular platforms (CCAMP) and Department of IT,BT and ST, Govt of Karnataka. We work on Bio Modified silk proteins to develop various innovative medical devices / other products for Advanced and Active wound care management addressing non healing, slow healing and difficult to heal acute and chronic wounds. We have been recognised by BIRAC for our innovation and commercialising a patented product from Silk Protein which assists in faster healing of wounds through higher scaffold formation and tissue regeneration. We aspire to be a comprehensive Woundcare company addressing various types of wounds and make a difference with our unique meaningful science. Look forward to make a difference in woundcare space and passing on the benefits of economic multiplier potential of Silk and silk proteins to the masses while being most comprehensive woundcare company from India.

GangaGen Biotechnologies Private Limited, India (GBPL), is a biologics company specialized in discovering, designing and developing novel treatments for drug-resistant bacterial infections. The company is focused on developing products for the prevention and treatment of bacterial infections, including pneumonia caused by multidrug-resistant bacteria. GangaGen is a clinical-stage biotechnology company with a focus on developing novel therapeutic proteins.

GeneSys Biologics was established in Nov 2014 by a group of like-minded individuals with strong global experience in development of biosimilars. A science-based biosimilar company with the vision of becoming one of the leading global biopharmaceutical companies in the world. GeneSys aims to expand market access across the globe by providing affordable and high quality biosimilars.

Gennova Biopharmaceuticals Ltd. is a biotechnology company based in Pune, Maharashtra, India. The company specializes in the research, development, production, and commercialization of biotherapeutics and vaccines aimed at treating life-threatening diseases in areas such as cardiovascular, neurology, nephrology, and oncology. Gennova employs advanced recombinant DNA technologies and innovative bio-manufacturing practices to create effective biotherapeutic solutions. The company utilizes various expression platforms, including bacterial, mammalian, and yeast-based systems, to produce its recombinant products. Gennova has successfully commercialized seven products, including Tenectase, a biosimilar for treating Acute Ischemic Stroke, and HAMSYL, a treatment for acute lymphoblastic lymphoma offered at a lower price point for better accessibility. With a strong focus on research and development, Gennova is recognized as a preferred partner in the vaccine sector for research and cGMP manufacturing. The company employs around 598 people and has reported a revenue of $2.8 million, positioning itself as a notable player in the Indian biotechnology landscape.

Established in Hyderabad, India in 1978, Gland Pharma is one of the fastest-growing small-molecule generic injectables-focused company, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets in the rest of the world. Gland Pharma has seven manufacturing facilities in India, comprising four facilities for finished formulations and three API facilities. We are focused on meeting diverse injectables needs with a stable supply of affordable and high-quality products. We have established a portfolio of injectables products across various therapeutic segments and delivery systems and are present in sterile injectables, oncology and ophthalmics with a focus on complex injectables.

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark's culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark's core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation' (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

A pioneering clinical stage startup company leading the Cell & Gene therapy revolution and are committed to bringing breakthrough cancer treatment to patients in India, making it accessible & affordable.

ImmunoACT, also known as ImmunoAdoptive Cell Therapy Private Limited, is an Indian biotechnology company specializing in cell and gene therapies. Founded by Dr. Rahul Purwar and Dr. Atharva Karulkar, the company aims to provide affordable access to innovative autologous Chimeric Antigen Receptor (CAR) T-cell therapies. It originated as a spin-off from the Indian Institute of Technology Bombay and is incubated at the Society for Innovation and Entrepreneurship. The company focuses on translational research and development in cell and gene therapy. One of its notable products is NexCAR19, a cost-effective version of CAR-T therapy aimed at treating leukemia and lymphoma. ImmunoACT is committed to expanding its impact through partnerships, such as its collaboration with Caring Cross to commercialize TriCAR T-cell immunotherapy. The company strives to make advanced therapies more accessible to patients in India and beyond.

Indian Immunologicals Ltd (IIL) is the market leader in veterinary and human biologicals in India. It manufactures over 150+ products. IIL operates one of the largest plants in the world for veterinary vaccines. IIL has adequate infrastructure and cold chain distribution capability to reach out to various parts of India and world market. This flexibility in logistics has ensured many products of IIL occupy top slots in the market. IIL is a major player in the human vaccine market in India, focusing on the pediatric and rabies vaccine segments. IIL is also a major supplier of pediatric vaccines to India’s large Universal Immunization Programme. Brief History of IIL: Indian Immunologicals was established by the National Dairy Development Board (NDDB) in 1982, as its unit, with the objective of making vaccines available to farmers at an affordable price. The unit was incorporated as Indian Immunologicals Limited in the year 1999. IIL started manufacturing human vaccines in 1998 on a specific request by the Government of India. IIL is the second company in the world and first in India to launch purified vero cell rabies vaccine (PVRV) and markets it under the brand – Abhayrab. This led to the discontinuation of use of older and unsafe sheep brain derived vaccine (also termed Nerve Tissue Vaccine – NTV) in the country. IIL has also been exporting Animal Health vaccines,formulations & Human Health vaccines, to more than 50 countries. IIL not only provides products and services to enhance the quality of livestock in the country, but also utilizes its technological capabilities for the benefit of the people.

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

ISSAR’S purpose lies in the development of new technologies at an affordable price to improve quality of life for Indian population. With over 25 years of experience and prime focus in Research and Development, ISSAR’S dedicated team of experts are proud to have developed India’s first ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR’S commitment has also led to the development of their second New Chemical Entity called Xylentra®, which is the first ever peptide drug in the world for the treatment of burn wounds and microbial infections.Recently, ISSAR has also developed molecules for prevalent conditions in the Western world such as Inflammatory Bowel Diseases (IBD), Psoriasis and Sepsis. The future holds an extensive place for peptides as safe and efficient therapeutics with excellent diagnostic, preventive and curative properties. ISSAR is the only pharmaceutical company working as a purely peptide manufacturing technology based company with an FDA- compliant state-of-the-art manufacturing facility of 62000 sq. ft. located in Genome valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automated technology for synthesis and purification of peptides, producing highest standards of purity of up to 99.5% by continued process optimization. ISSAR uses Solid phase peptide synthesis as the technology of choice with a long-standing expertise in custom peptide synthesis at all scales. With our emphasis on quality, safety and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology and diseases of bones and joints.

Laurus labs is an innovation-driven¸ people-centric & client-focused organization offering a broad and integrated portfolio of products & services to the global pharmaceutical industry. Equipped with a world-class infrastructure manned by best-in-class personnel & driven by the core values of knowledge, innovation and excellence, within a relatively short period, Laurus labs emerged as a segment-leading manufacturer of high quality APIs, a preferred partner for NCE development & manufacture & a trusted source of specialty ingredients for the nutraceutical industry. Given the strengths, capabilities & experience, Laurus Labs is uniquely positioned to help its clients in their endeavor of ‘quicker to market' & thus contributing towards improving access to quality & affordable healthcare worldwide.

Lazuline Biotech Private Limited is a research-driven and quality-focused biomanufacturer with a focus on improving the human health by catering to the needs of the healthcare and biopharma industries. Our world-class R&D and cGMP manufacturing facility in Hyderabad, India has enabled us to develop a range of Recombinant and Biological products. Founded in 2011, through the years we have been able to differentiate ourselves with our product-oriented focus and global partnerships. Through continuous innovations and single-pointed focus, we are proud to be producing the highest capacity in the world at economical pricing for the global market.

Morepen Laboratories Limited is an Indian pharmaceutical company founded in 1984. It focuses on providing affordable and high-quality healthcare solutions through innovative pharmaceutical and medical technology products. The company is committed to excellence and aims to make health accessible worldwide. Morepen offers a diverse range of products, including high-quality Active Pharmaceutical Ingredients (APIs) such as Loratadine and Atorvastatin, as well as formulation products across various therapeutic categories like antibiotics and analgesics. The company also has a strong presence in the medical devices sector, particularly with its Blood Glucose and Blood Pressure Monitors. Morepen operates three manufacturing plants in Himachal Pradesh, India, and has a well-equipped R&D center that emphasizes innovation. With a robust distribution network of over 5,100 distributors and 328,000 retail touchpoints in India, Morepen exports its products to more than 50 countries, establishing itself as a significant player in the global generic drug market.

MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 22 state-of-the-art manufacturing facilities (15 API and 7 Finished Dosage Facilities) established across India and USA. The group has an integrated R&D centre that facilitates the research of both API and Finished Dosages under one roof, enabling the organization to introduce new and affordable therapies in global markets swiftly. Backed by a dedicated and experienced team of over 14,000 qualified professionals, the organization has earned a global distinction for its innovation, quality and speed of delivery besides achieving the following: > About 900+ national and international patent applications filed > Product portfolio of 450 + APIs & 300+ Finished Dosages > Over 35 major therapeutic offerings covering Oncology, Cardiology, CNS, Diabetes, Nephrology, Urology, Gastroenterology, Orthopaedics etc. > World No. 1 in active US DMF Filings > Won the trust of more than 40 Million patients across 100+ countries The organizational environment at MSN Labs integrates multiple disciplines and functions by effective implementation of goals and objectives through technology coupled with Integrity, Imagination and Innovation. The company's proactive marketing, robust IP strategy, innovative R&D expertise, dynamic SCM, Insight-driven IT, and world-class facilities remain at the heart of its continuing success. We own a track record of growing at an exponential pace since our inception. From 22 Million USD in 2005 to achieving about 670 Million USD turnover in FY 2021-22 and counting, we continue to expand our growth and global footprint by creating innovative solutions for tomorrow's healthcare requirements.

Mynvax is a developer of novel recombinant vaccines to fight the human influenza virus and COVID19. The company is focused on developing next-generation vaccines for influenza and other respiratory viruses. Mynvax has raised a total funding of $7.22M over 3 rounds from various investors. It is a clinical stage vaccine biotechnology company with a vision to create efficacious vaccines for respiratory viruses.

NATCO Pharma is a vertically integrated company dedicated to the development, manufacture, and supply of pharmaceutical and agrochemical products. Established with the mission to make specialty medicines accessible to all, we are rooted in integrity, respect, openness, collaboration, creativity, and quality. Founded in 1981, we now have a strong global presence in over 50 countries. NATCO has emerged as an esteemed pharmaceutical company with a presence in Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs) in both domestic and international markets. NATCO Pharma's focused approach has led to expanded capabilities across diverse therapy segments, particularly in oncology. We operate in two key segments: Pharmaceuticals and Agrochemicals. Our expertise excels in the FDF division, crafting intricate pharmaceutical solutions tailored to specific therapeutic needs. In the manufacturing of APIs, we maintain high quality and adhere to all regulatory standards with a focus on innovation. In the Crop Health Sciences (CHS) division, we produce high-value agricultural input products to meet farmers' demands, including environmentally safer biocontrol products. Operating globally, NATCO's work contributes to its diverse market presence. NATCO believes in sustainable and balanced growth through the synergy of our talented workforce and an innovative culture. We are dedicated to maximizing shareholder value creation through innovation, employee engagement, process and system optimization.

Panacea Biotec is a research-based health management company involved in research, manufacturing and marketing of high-quality, affordable pharmaceutical, vaccines and herbal products. The product portfolio includes highly innovative prescription products in important therapeutic areas like pain management, diabetes, cardiovascular, renal disease management, osteoporosis, gastro-intestinal care products and vaccines. Panacea Biotec is committed towards disease prevention by introducing Innovative Vaccines that helps to reduce child mortality. Our portfolio consists of worlds first fully liquid Hexavalent vaccine i.e. EasySix (DTwP-Hib-HepB-IPV), the world’s first fully-liquid Pentavalent vaccine i.e. Easyfive-TT (DTwP-Hib-HepB), Oral Polio vaccines (like bOPV, tOPV, mOPV), etc. We have a high-impact pipeline of vaccines including Pneumococcal conjugate vaccines (PCV), tetravalent dengue vaccine, etc. We have supplied 10+ billion immunizations of Polio vaccines in last 20 years, 150+ million immunizations of Novel Innovative fully liquid wP-based vaccines like the wP-Hexavalent vaccine (DTwP-Hib-HepB-IPV). And are a trusted partner for WHO, GAVI and UN Agencies with track-record of sustainable supplies for UNICEF, PAHO, and National Immunization Programs. In Pharmaceuticals, we have discovered and commercialised a NCE, Sitcom – that helps in Haemorrhoids and Piles. It is the leading brand in its segment in India and many other countries. We also have built leading brands like Pangraf, Mycept, Glizid, Livoluk, and PacliAll across transplantation, diabetes, constipation, and oncology. Our facilities are WHO Prequalified, US FDA approved and cGMP compliant. Our products are available across more than 145 countries including US, Germany, among other markets.

Pandorum is a biotechnology company based out of the US and India, working in the field of Tissue Engineering and Regenerative Medicine. With its distinct synergy of life science, engineering and clinical competences, at Pandorum, we have developed a proprietary technology platform which combines therapeutic exosomes with anti-inflammatory, anti-fibrotic properties derived from clinical grade human stem cells and biomaterials with tissue-mimetic properties – to promote efficient regeneration of human tissues, such as cornea, liver and lung. Pandorum has been supported by a number of Govt. grants (BIG, SBIRI) and awards, and have raised funding from marquee investors and VCs. We are proud to have a world-class team of scientists, engineers, clinicians, and key opinion leaders deeply engaged in the product development and clinical translation. Pandorum's efforts towards clinical translation of its products have been supported by renowned medical Institutions such as, are Northwestern Medicine (Chicago, US), Medical University of South Carolina (Charleston, US) and Dr. Shroff’s Charity Eye Hospital (New Delhi, India). Pandorum is also proud to be an Endless Frontier Labs (EFL) start-up, NYU Stern School of Business, Life Sciences Cohort -2023. At Pandorum our efforts are dedicated to make Regenerative Medicine an efficacious and scalable mainstream reality, to be able to address the sufferings of millions across the globe affected by various diseases of unmet clinical needs

Reliance Life Sciences is a medical biotechnology-led company engaged in research and development, manufacturing and marketing of differentiated medical products and services, used to treat patients primarily in intensive and critical care units in hospitals. Our core businesses are plasma proteins, biosimilars, and later generation oncology pharmaceuticals. In addition, we have initiatives in clinical research, molecular medicine, regenerative medicine, gene therapy, peptides and oligonucleotides.

RenaissThera is a pharmaceutical company dedicated to developing affordable, novel small-molecule targeted therapies leveraging AI platforms. Our goal is to innovate for underserved populations and bridge the gaps in novel therapy access worldwide. We focus on high-unmet-need areas of prevalent diseases in cardio-metabolic therapy including diabetes type 2 and obesity. Leveraging our Innovation Platform powered by GenAI tools, we identify small-molecule therapies for proven pathways, ensuring cutting-edge solutions for patients. With a leadership team and scientific advisory board boasting extensive experience in global pharmaceutical product development, RenaissThera is committed to bringing innovative treatments to those in need around the world.

Satya is a DDR focused drug discovery company, and has pioneered RAD51 inhibition as a potentially foundational therapeutic for high replication stress solid tumors. In addition to first- and best-in-class DDR programs, Satya additionally focuses on targeted pan-cancer therapeutics that can address a wide variety of tumors Satya's world-class scientific team is driven by a commitment to excellence, and has experience of working on over 75 targets that have led to over 15 global clinical programs, including one FDA-approved oncology drug

SciGen is a rapidly growing biopharmaceutical company that markets and commercializes innovative and affordable healthcare products worldwide. We leverage our commercialization and networking capabilities to in-licenses and distribute branded pharmaceutical products and medical devices to treat endocrinological and oncological diseases, and continuously fill and improve our pipeline and product portfolio. Founded in the Asian Innovation Capital, Singapore in 1988, we currently have operations in Singapore, South Korea, Australia, China, Philippines and present commercially in all 6 continents. With the exceptional commercialization capabilities, regulatory expertise as well as international management experiences, and strategic partnerships built with industry and academic institutes, we strive to deliver hope and make a real and lasting difference to patients and their families. Who are we? - We believe in delivering solutions that matter to the people of today and innovating for the people of tomorrow. - To us, it is more than a business - it is a mission. What do we do? - We combine a specialty pharmaceutical business with a leading biologics biotechnology engine. - We partner to bring the best drugs we can find to the patients who need it most. How do we do it? - Our efforts aim to deliver better patient outcomes through better science. - We understand that humility and service matter as it is not about us, it is about making patients’ lives better.

Sphaera Pharma, founded in 2008, is an integrated drug discovery and development organization led by pharma and biotech professionals with global experience. Our goal is to bring innovative therapies to patients with unmet medical needs by developing a balanced portfolio of early stage discovery projects and clinical programs. Sphaera’s research facility in India has established in-house capabilities in ALL aspects of pre-clinical drug discovery and development. Our external alliances allow reliable access to specialized services such as in radio-chemistry, c-GMP manufacture, GLP studies, clinical formulations, structural biology and clinical development.

StemGenn Therapeutics is leading the research and Development of efficient and affordable Cell Therapy ,Preventive & Personalized Functional Medicine for a wide range of Metabolic, Auto immune & Lifestyle conditions . StemGenn Aiming for Develop personalised Products for Cosmetic Gynecology, Infertility & Aesthetic Medicine. StemGenn Provides Personalized Care for Men’s Health for their Complete care from Skin, Diet to Sexual Health( Erectile Dysfunction). StemGenn Started exclusive Training Program to doctors , scientists and researchers for Regenerative Medicine, PRP, Cosmetic Gynecology( Vulvo-Vaginal Rejuvenation), Aesthetic Medicine, Laser, Radio Frequency and Bio-Revitalisation techniques first time in India . Stemgenn’s vision is to create a better and healthy world with cellular therapies and regenerative medicines. We aim at leveraging the benefits of stem cell therapy for anti-aging. Our core values consist of Caring, Safety, Excellence and Integrity for creating a healthy tomorrow."​ Mission: Contribute to human health by enabling technologies using Regenerative Medicine. Training programs are developed by our scientists and team of clinicians with the aim to overcome challenges in your experimental/ clinical procedures and advance your research and Therapeutics.We are Scientists Helping Scientists and doctors .Our highly interactive technical training is current with the latest tools and protocols, designed specifically for your needs. Contact : +91 9811011690, Email: contact@stemgenn.com

Stempeutics is a leading Regenerative Medicine company in Bangalore with our patented stem-cell therapy platform technology developing treatment of cardiovascular, immune-mediated and degenerative diseases. The company's flagship product, Stempeucel® has received market authorization to treat Critical Limb Ischemia – a major unmet medical need in India. It is the FIRST innovative cell therapy based product to get marketing approval in India and Globally. CIPLA, the Indian licensee, has commenced pan-India commercialization. It has the FIRST DCGI approved Cell therapy product for Knee Osteoarthritis being marketed by Alkem. Stempeutics has a product in the Phase 3 stage covering Diabetic Foot Ulcer. Further it is conducting Phase 2 trial in Perianal fistula due to Crohn’s disease. Stempeucel® has strong patent protection with 20 patents granted including US, Europe and Japan. Stempeucel® has been classified as an Advanced Therapy Medicinal Product (ATMP) and designated as an Orphan Drug for the treatment of CLI due to Buerger’s Disease by the European Medicines Agency (EMA) Another portfolio developed by Stempeutics is Stempeucare® range of cosmetics. It is developed from the stem cell derived Growth Factors/Cytokines combination for various cosmetic and derma applications including rejuvenation of aging skin, hair fall control & hair growth promotion, under eye dark circle reduction cream etc. First product which has gone to the market is an intensive firming skin care cosmetic product, branded as Cutisera™. Other products ready for marketing are Trichosera™ for Hair application and Optisera™ for under eye application With a strong pipeline in Cell and Gene therapy products in some of the largest health and personal care segments like OTC Cosmetics (Skin and Hair Care), Osteoarthritis, Diabetes, CLI and PAF Stempeutics is poised to transform the Cell & Gene therapy space with its India First, Global Next approach.

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is a prominent global pharmaceutical company based in India. Established in 1983, it has grown to become the largest pharmaceutical company in India and the fifth-largest specialty generic pharmaceutical company worldwide. Sun Pharma specializes in generic and specialty pharmaceuticals, focusing on chronic therapies in areas such as cardiology, psychiatry, neurology, gastroenterology, and oncology. The company operates in over 100 countries, with significant markets in the U.S., India, and emerging economies. Sun Pharma produces a diverse range of off-patent generic drugs, including tablets, capsules, injectables, and topical formulations. It also develops complex generics and specialty products for various conditions. The company has a strong commitment to research and development, investing in novel drug delivery systems and biosimilars. With 43 manufacturing facilities across five continents and a workforce of over 37,000, Sun Pharma continues to expand its global footprint and enhance its product offerings.

Tenshi Kaizen(TK or Tenshi) is focussed on delivering advanced finished dosage products driven by proprietary technology platforms, global infrastructure, and a robust quality system. Our strategy is aligned with the founder's ethos of producing reliable and cost-effective pharmaceuticals with speed and agility. As of today, Tenshi Kaizen has investments in three proprietary technology platforms viz. InstaPillTM technology for rapid dissolve tabs, the world's first thermostable probiotics platform(Under Triphase) , and proprietary technology to extract and develop highly bioavailable natural products(Under Olene Life Sciences) Building on our strong global network, we are committed to fulfilling the demands of the world markets by anticipating the future needs and pioneering strategic new in-roads into the commercial pharmaceutical sector. Please visit www.tenshi.co.in

Transcell Biologics is an innovative biotech company with continuous discovery and process development as it's central theme to deliver unique disruptive stem cell based solutions to treat chronic and debilitating diseases that have otherwise no options available to manage. The passionate leadership team is committed to developing therapies to address important medical needs through adult stem cell technologies by collaborating with clinicians and patient communities. Among the company's landmark innovations is the development of a novel proprietary process for maximizing the therapeutic stem cell yield that also maintains the native pluripotent properties and inherent functionality. The Company has evolved from solely an R&D-focused biotech entity diversifying based on the intended applications of stem cell technologies.

Burden of medicine bills is a leading cause of financial worry among Indian consumers ● 70% of healthcare spend in India is on Medicines ● 15-20% of family income of chronic patients is spent on medicines ● 63 million people in India plunge into poverty annually due to healthcare costs Our vision is to make healthcare affordable and accessible to all. We are a technology driven, tele-health platform that aims to reduce healthcare expenses and improve healthcare outcomes by democratising medicine purchase in India. Truemeds, through its proprietary algorithm and tele-consultation, is able to recommend best value medicines to customers with precise scientific matching and outcomes history leading up to 51% savings for customers! We have grown at a phenomenal pace with customer love – 60X growth delivered in last 20 months. Headquartered in Mumbai, we are excited to build a strong product and operations team, which is passionate to build innovative solutions and willing to go the extra mile to ensure the customer has the best experience.

Turtle Pharma is a Private Pharmaceutical Company, with Headquarters in Mumbai, and Plant located near Vadodara, Gujarat, engaged in manufacturing of Active Pharmaceutical Ingredients. Turtle Pharma Private Limited Our main aim is to manufacture Active Pharmaceutical Ingredients, in conformity with regulations in force concerning the quality of pharmaceutical products, environment, safety and the health of consumers and citizens.

Tvaster Genkalp is a Molecular Diagnostics company, established in May 2021, specialising in Liquid Biopsy, offering blood based cancer diagnostic solutions. With innovative approach and commitment to quality, Tvaster has developed a groundbreaking screening test for Hepatocellular carcinoma (HCC) called Episcreen™ Liver. Episcreen™ Liver represents a major leap forward in the early detection of liver cancer (HCC). Rigorously validated through a study involving over 750 patients, this technology has demonstrated exceptional accuracy, far surpassing the current standard blood-based biomarker, AFP. The recent clinical study revealed that Episcreen™ Liver achieved an impressive sensitivity of 90%, in stark contrast to AFP's 50%. Moreover, Episcreen™ Liver identified 92% of HCC cases missed by AFP, offering a potentially life-saving solution for countless individuals. Tvaster is dedicated to enhancing early cancer detection and improving patient outcomes through its state-of-the-art diagnostic solutions.

Vgenomics is an Indian company that aims to diagnose rare diseases with bioinformatics and artificial intelligence (AI). They are committed to addressing rare diseases and improving patient outcomes by analyzing complex genetic information. Vgenomics develops diagnostic and therapeutic solutions for inborn diseases, leveraging genomics and AI to bring novel solutions to the market for over 175 million children suffering from rare diseases.

Vopec Pharmaceuticals Private Ltd. is a pioneering company which is manufacturing Ayurveda and siddha formulations, and was established in the year 1996. Vopec pharma has taken up a leading role in the formulations re-establishing ancient knowledge with modern Research and manufacturing techniques. The company is located in Aminjikarai, Chennai having GMP Certificate and FSSA licence to manufacture nutraceuticals. Vopec also have licence to manufacture Ayurvedic and Siddha formulations including Sasthric products and Food supplements. Vopec is a stake holder in Traditional Ayush Cluster of Tamilnadu (P) Ltd., precisely called TACT. Vopec Pharmaceuticals has various herbal capsules, syrups and pain relieving oils like Nart Capsule, Asmask Capsules, Dyzee Syrup etc. Another exciting program that Vopec provides are the consultation slots with Ayurveda experts, where one can mention their problems or issues and get effective solutions within minutes.

Wockhardt is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Specialty Hospitals. Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 3000 Wockhardt Associates from 21 different nationalities globally. It has 3 research centers and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. Headquartered in Mumbai, India, Wockhardt has full-fledged operations in the USA, UK, Ireland and France. It also has its marketing presence in emerging markets of Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. Wockhardt’s core business is innovation. It uses science and technology to develop medicines and other products that improve the quality of millions people’s lives through better health. Wockhardt aspires to create a healthier world. Its strategic vision of ‘More & More with Less & Less’ has transformed into new ways of thinking, a new journey for growth, medical breakthroughs for patients and continuing value for all stakeholders.